Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

venues in 2008, we are projecting an operating loss of DKK 900 to 1,000 million compared to the DKK 437 million reported for 2007. Under the conditions described above, the net loss for 2008 is expected to be in the range of DKK 800 to 900 million compared to the net loss of DKK 383 million reported for 2007.

As of December 31, 2007, Genmab had cash, cash equivalents and short-term marketable securities of DKK 3.7 billion (approximately USD 728 million). We expect the 2008 cash burn to consist of USD 240 million (approximately DKK 1.2 billion) paid for the acquisition of the manufacturing facility, operational expenses of approximately DKK 750-800 million (approximately USD 148-158 million) and approximately DKK 40-50 million (approximately USD 8-10 million) in other capital expenditures. We expect to spend over 90% of our 2008 budget on research and development, including the operation of our manufacturing facility and less than 10% on general and administrative expenses. Of the research and development costs, we expect to spend approximately DKK 500 million (approximately USD 98 million) on development for the ofatumumab program.

Total projected revenues for 2008 are expected to be approximately DKK 1.0 billion (approximately USD 197 million), an increase of approximately DKK 470 million (approximately USD 93 million) over 2007 revenues, which were 530 million (approximately USD 104 million). Net financial income is expected to be approximately DKK 70-75 million (approximately USD 14-15 million). Thus, including the manufacturing acquisition and operational expenses, we are projecting a 2008 year end cash position of DKK 1.7 to 1.8 billion (approximately USD 335 to 355 million).

The estimates above are subject to possible change primarily due to the timing and variation of development activities, related income and costs and fluctuating exchange rates. Our projected 2008 revenues consist primarily of milestone payments, for which we cannot alw
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and SOUTH SAN FRANCISCO, Calif. ... the venture arm of Baxter International Inc. (NYSE: ... LLC ("VPD") today announced the formation of Vitesse Biologics, ... by Baxter Ventures to focus on the development of ... hematology, and oncology. Following the spin-off of Baxter BioScience ...
(Date:6/1/2015)... /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") today ... the ERA-EDTA Congress in London, England ... First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects ... (CKD); a Post-hoc Analysis of Patients from the ASSERT, ... Kam Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension ...
(Date:6/1/2015)... , June 1, 2015   Epic Sciences, ... develops products and offerings to personalize and advance the ... has expanded the available credit under its existing credit ... amended agreement increases the available capacity of the facility ... the maturity by 27 months to April 1, 2019. ...
(Date:6/1/2015)... , May 29, 2015 Research ... the addition of the "2015 Strategies ... report to their offering. This ... European immunoprotein diagnostic market, including emerging tests, ... strategic profiles of leading suppliers. ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Sept. 10 Abeome Corporation, a,Georgia-based biotech company, ... (SAB) to collaborate on the development of,Abeome,s ovarian ... therapeutic,and diagnostic projects for the company., The ... Meagher, PhD, Chief,Scientific Officer for Abeome, Distinguished Research ...
... Generation of Drug Candidates ... for Inflammatory Diseases, ... Cellzome Inc. and GlaxoSmithKline (LSE & NYSE:,GSK) announce the ... novel kinase-targeted therapeutics to treat inflammatory,diseases., The alliance gives ...
... Sept. 9 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced that RiskMetrics ISS ... they have no,objection to the transaction, and are ... the proposed plan of arrangement whereby Roche,will acquire ...
Cached Biology Technology:Abeome Forms First Class Scientific Advisory Board 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 3GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 4Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 2Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 3
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... Manipulation of cells by a new microfluidic device may ... the body,s own immune cells to fight such diseases ... neuroblastoma. The therapy, known as adoptive T cell ... treatment involves removing disease-fighting immune cells called T cells ...
... engineered bacteria to churn out a gasoline-like biofuel at ... breakthrough that could soon provide an affordable and "green" ... week in advance of publication in the journal ... assistant professor of chemistry at UC Berkeley, graduate student ...
... NJ The American Heart Association estimates 35 percent of ... of risk factors characterized by obesity and the simultaneous presence ... sugar and lipids. In patients with metabolic syndrome, high ... in turn affects the organ,s ability to filter waste from ...
Cached Biology News:Researchers predict age of T cells to improve cancer treatment 2Researchers predict age of T cells to improve cancer treatment 3Turning bacteria into butanol biofuel factories 2Turning bacteria into butanol biofuel factories 3Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 2Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 3
Buffer used for mitocapture assays....
... CyScribe GFX Purification Kit, 25 ... CyDye labeled cDNA probesProvides efficient removal ... from labeling reactions with superior yields ... for the purification of cDNA labeled ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Biology Products: